Stock Events

Stock Events

Helus Pharma 

$4.66
468
-$0.42-8.27% Friday 19:59

Statistics

Day High
4.99
Day Low
4.64
52W High
9.83
52W Low
4.29
Volume
1,597,253
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1JulExpected
Q3 2025
Q4 2025
Next
-1.36
-1.16
-0.96
-0.76
Expected EPS
-0.79684805232
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-160.34MNet Income

Analyst Ratings

49Average Price Target
The highest estimate is 95.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HELP. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.34B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Cybin's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap1.48B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor to Cybin.
GH Research
GHRS
Mkt Cap1.47B
GH Research is involved in the development of therapeutics based on DMT for depression, competing in the same psychedelic treatment space as Cybin.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including psilocybin and MDMA, competing in the mental health treatment market alongside Cybin.
Revive Therapeutics
RVVTF
Mkt Cap9.58M
Revive Therapeutics is exploring the use of psychedelics for the treatment of various conditions, including mental health disorders, making it a competitor to Cybin.
PSYC
PSYC
Mkt Cap135,518
Psyched Wellness is focused on the development of psychedelic products, including Amanita Muscaria, competing in the broader psychedelic wellness market.
TripAdvisor
TRIP
Mkt Cap1.22B
Red Light Holland is involved in the production, growth, and sale of a premium brand of magic truffles, competing in the psychedelic substances market relevant to Cybin's interests.

About

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Eric So L.L.B.
Employees
50
Country
United States
ISIN
CA23256X4075

Listings

STU
DE
R7E.STU
MU
DE
R7E.MU
XNAS
US
HELP
F
DE
R7E.F

0 Comments

Share your thoughts

FAQ

What is Helus Pharma stock price today?▼
The current price of HELP is $4.66 USD — it has decreased by -8.27% in the past 24 hours. Watch Helus Pharma stock price performance more closely on the chart.
What is Helus Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Helus Pharma stocks are traded under the ticker HELP.
When is the next Helus Pharma earnings date?▼
Helus Pharma is going to release the next earnings report on July 01, 2026.
What were Helus Pharma earnings last quarter?▼
HELP earnings for the last quarter are -0.99 USD per share, whereas the estimation was -0.76 USD resulting in a -30.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Helus Pharma revenue for the last year?▼
Helus Pharma revenue for the last year amounts to 0 USD.
What is Helus Pharma net income for the last year?▼
HELP net income for the last year is -160.34M USD.
How many employees does Helus Pharma have?▼
As of May 17, 2026, the company has 50 employees.
In which sector is Helus Pharma located?▼
Helus Pharma operates in the Health & Wellness sector.
When did Helus Pharma complete a stock split?▼
Helus Pharma has not had any recent stock splits.
Where is Helus Pharma headquartered?▼
Helus Pharma is headquartered in Toronto, United States.